Zelluna ASA (OSL:ZLNA)

Market Cap	493.35M +20.1%
Revenue (ttm)	n/a
Net Income	-140.71M
EPS	-7.08
Shares Out	26.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,563
Average Volume	59,157
Open	18.78
Previous Close	18.78
Day's Range	18.78 - 19.26
52-Week Range	8.20 - 22.50
Beta	n/a
RSI	56.97
Earnings Date	Mar 25, 2026

About Zelluna ASA

Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101); and collaboration with Etcembly Ltd for AI-enabled TCR engineering. The company was founded in 2016 and is based in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 24
• Stock Exchange: Oslo Børs
• Ticker Symbol: ZLNA